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A B S T R A C T
AKN-028 is a novel tyrosine kinase inhibitor with preclinical activity in acute myeloid leukemia (AML),
presently undergoing investigation in a phase I/II study. It is a potent inhibitor of the FMS-like kinase 3
(FLT3) but shows in vitro activity in a wide range of AML samples. In the present study, we have
characterized the effects of AKN-028 on AML cells in more detail. AKN-028 induced a dose-dependent G0/
1 arrest in AML cell line MV4-11. Treatment with AKN-028 caused signiﬁcantly altered gene expression
in all AML cell types tested (430 downregulated, 280 upregulated transcripts). Subsequent gene set
enrichment analysis revealed enrichment of genes associated with the proto-oncogene and cell cycle
regulator c-Myc among the downregulated genes in both AKN-028 and midostaurin treated cells. Kinase
activity proﬁling in AML cell lines and primary AML samples showed that tyrosine kinase activity, but
not serine/threonine kinase activity, was inhibited by AKN-028 in a dose dependent manner in all
samples tested, reaching approximately the same level of kinase activity. Cells sensitive to AKN-028
showed a higher overall tyrosine kinase activity than more resistant ones, whereas serine/threonine
kinase activity was similar for all primary AML samples.
In summary, AKN-028 induces cell cycle arrest in AML cells, downregulates Myc-associated genes and
affect several signaling pathways. AML cells with high global tyrosine kinase activity seem to be more
sensitive to the cytotoxic effect of AKN-028 in vitro.
 2013 The Authors. Published by Elsevier Inc. 
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Open access under CC BY license.1. Introduction
Acute myeloid leukemia (AML) is a life-threatening neoplastic
disease characterized by several acquired genetic abnormalities
and with multiple signaling pathways involved in the pathogene-
sis. Treatment in AML is still based on cytotoxic chemotherapy, but
much effort is now being put in the identiﬁcation of molecular drug
targets, allowing more speciﬁc therapeutic approaches in this
disease. However, progress in AML treatment has been slow and
the long-term survival remains poor [1,2].* Corresponding author at: Division of Hematology (50C), Uppsala University
Hospital, SE-751 85 Uppsala, Sweden. Tel.: +46 186110000; fax: +46 18502916.
E-mail address: anna.eriksson@medsci.uu.se (A. Eriksson).
0006-2952  2013  The  Authors.  Published by Elsevier Inc.   
http://dx.doi.org/10.1016/j.bcp.2013.10.022
Open access under CC BY license.We have previously reported on AKN-028; a novel tyrosine
kinase inhibitor (TKI), designed as an ATP-mimetic and with potent
in vitro and in vivo activity in AML and presently undergoing
investigation in an international two-part multi-center phase I/II
clinical study (ClinicalTrials.gov NCT01573247) [3]. AKN-028 is a
potent inhibitor of the FMS-like kinase 3 (FLT3) with an IC50 of
6 nM in a biochemical assay, and also an inhibitor of KIT kinase
autophosphorylation when investigated in a cellular assay [3].
AKN-028 displays in vitro anti-leukemic effect resulting in cell
death in tumor samples from a wide range of AML patients,
irrespective of FLT3 mutation status or level of quantitative FLT3
expression. This prompted us to further investigate the mechanism
of action of AKN-028 in AML.
AKN-028 displays a sequence dependent in vitro synergy with
the conventional cytotoxic agents cytarabine and daunorubicin,
with better antileukemic activity when the cells are exposed to
standard chemotherapy simultaneously or for 24 h before adding 
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treated with AKN-028 [3]. The latter is in accordance with results
reported for other TKIs, and may be explained by the fact that
TKIs can cause cell cycle arrest [4]. This, along with our previous
ﬁnding that AKN-028 in biochemical assays also inhibits CDC-like
kinase 1 (CLK1) with an IC50 of 140 nM and the mTOR mediator
ribosomal protein 6 kinase (RPS6K) with an IC50 of 220 nM [3], led
us to explore the possible cell cycle effects of AKN-028 in more
detail, especially since RPS6 K is involved in both mTOR
dependent cell cycle control and effective G1 cell cycle progression
[5,6].
Genome wide expression analysis using microarray tech-
nique has become an important tool in genomic research and a
method widely used in mechanism of action studies of new
compounds [7]. To analyze data from microarray studies, one
can take advantage of gene set enrichment analysis (GSEA) that
derives its strength from focusing on whole gene sets, linked by
common biological features, chromosomal location or regula-
tion. The aim of a GSEA is to determine whether members of a
predeﬁned gene set (e.g. genes linked by a speciﬁc signaling
pathway) are enriched at the extremes (top/bottom) of a pre-
ranked gene list [8].
AKN-028 displays a diagnose-speciﬁc in vitro efﬁcacy in AML
cell lines, which might in part be attributed to FLT3-inhibition [3].
However, the full in vitro efﬁcacy of a compound can rely on more
than direct target–compound interaction, for example inhibition
downstream of immediate interaction with a tyrosine kinase
receptor. The complexity of kinase signaling cascades, with their
intricate interconnected circuits, makes it necessary to study
compound effect on biochemical, cellular as well as organismal
level [9]. Global tyrosine kinase activity proﬁling has previously
been reported to contribute to improved understanding of
signaling pathways in leukemia, thereby offering a valuable
approach in identifying the mechanism of action involved,
following treatments with speciﬁc drugs [10,11].
The aim of the present study was to further characterize
pathways involved in the cell death induced by AKN-028 in AML
cells. Therefore, we have performed studies on cell cycle effects,
gene expression studies with subsequent analysis including GSEA,
as well as a global tyrosine kinase activation proﬁling in AML cell
lines and in primary AML tumor cells exposed to AKN-028.
2. Methods and materials
2.1. Reagents
AKN-028 (N-3-(1H-indol-5-yl)-5-pyridin-4-yl-pyrazine-2,3-di-
amine, provided by Akinion Pharmaceuticals, Stockholm, Sweden),
reference multikinase inhibitor midostaurin (purchased from LC
Laboratories, Woburn, MA, USA) and All-trans retinoic acid (ATRA,
Sigma–Aldrich Co, St. Louis, MO, USA) were stored at 70 8C as
10 mM stock solutions in dimethyl sulphoxide (DMSO, Sigma–
Aldrich) and further diluted with culture medium (Sigma–Aldrich)
as needed. The reference compound UCN01 (hydroxystaurosporin)
used in the serine/threonine kinase assay was purchased from
Enzo Life Sciences (Farmingdale, NY, USA).
2.2. Cell culture
Tumor cells from three patients with AML (Unique Patient
Number (UPN)) 1–3 were isolated by density gradient centrifugation,
stored at 150 8C in 10% DMSO and 90% heat-inactivated fetal calf
serum (FCS, Sigma–Aldrich) and then thawed at experimental setup.
The cells were maintained in RPMI-1640 medium supplemented
with 10% FCS, 2 mM glutamine, 100 mg/ml streptomycin and 100 U/
ml penicillin at 37 8C in humidiﬁed air containing 5% CO2 (allobtained from Sigma–Aldrich). The sampling was approved by the
Ethics Committee of Uppsala University (No. 21/93 and 2007/237).
AML cell lines MV4-11 (FLT3-ITD mutated) and HL60 (FLT3 wild
type), obtained from American Type Culture Collection (ATCC,
Rockville, MD, USA), were kept in Dulbecco’s modiﬁed Eagle’s
medium (Sigma–Aldrich) supplemented as above. The cell lines
were subcultivated twice weekly and the number of cells was
determined by trypan-blue counting.
2.3. Quantitative FLT3 expression analysis
The quantitative FLT3 expression of AML cell lines MV4-11 and
HL60 was determined as described previously [3]. The amount of
FLT3 transcripts was expressed as a ratio of FLT3 copy number
relative to 100 copies of reference gene GUSB (mean copy number
FLT3/mean copy number GUSB  100).
2.4. Fluorometric microculture cytotoxicity assay – FMCA
The cytotoxic activity of midostaurin was evaluated by use of the
ﬂuorometric microculture cytotoxicity assay (FMCA), described in
detail previously [12]. In short, this method measures hydrolysis of
ﬂuorescein diacetate to ﬂuorescein by cells with intact plasma
membranes. Primary AML samples or AML cell lines MV4-11 or
HL60 were incubated with serially diluted midostaurin at 37 8C.
Living cell density was assessed after 72 h with cell survival
presented as survival index (SI, %) deﬁned as ﬂuorescence in test
wells in percent of control cultures with blank values subtracted. The
half maximal inhibitory concentration (IC50) was determined from
log concentration-effect curves in Graph Pad Prism (GraphPad
software Inc., CA, USA) using non-linear regression analysis.
2.5. Cell cycle analysis
Preparation of cells and analysis of cell cycle distribution was
performed as described by Vindelov et al. [13]. Brieﬂy, cells were
seeded into 6 well plates and exposed to three concentrations of
AKN-028, ATRA (known to induce G0/1 cell cycle arrest [14]) or
vehicle control (DMSO). After three days, cells were washed with
phosphate buffered saline (PBS), treated with 0.03 mg/ml trypsin
(Sigma–Aldrich) for 10 min at room temperature, followed by
addition of 0.08 mg/ml RNase A (Sigma–Aldrich) and 0.5 mg/ml
trypsin inhibitor (Sigma–Aldrich). After an additional incubation of
10 min at room temperature, nuclei were stained with propidium
iodide (PI, 0.2 mg/ml, Calbiochem, San Diego, CA, USA) and
analyzed using a ﬂuorescence-activated cell sorting (FACS; BD
LSR II ﬂow cytometer, BD Biosciences, Franklin Lakes, NJ, USA) and
FACS DiVa software (BD Biosciences).
2.6. Gene expression analysis
Microarray analysis was performed as described by Lamb et al.
[15]. Brieﬂy, MV4-11, HL60 and leukemic cells from patient UPN2,
respectively, were seeded into 6 well plates at a density of 0.2
million cells/well and then grown for 24 h. The following day, cells
were exposed to AKN-028 or reference compound midostaurin at a
ﬁnal concentration of 10 mM or vehicle only (DMSO). Cells were
incubated for 6 h, washed with PBS and total RNA was prepared
using RNeasy1Mini Kit (Qiagen AB, Sollentuna, Sweden) according
to the manufacturer’s instructions.
The RNA concentration was measured with an ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA) and RNA quality was evaluated using the Agilent 2100
Bioanalyzer system (Agilent Technologies Inc., Palo Alto, CA, USA).
For the MV4-11 samples, 2 mg of total RNA from each sample were
used to prepare biotinylated fragmented cRNA according to the
A. Eriksson et al. / Biochemical Pharmacology 87 (2014) 284–291286GeneChip1 Expression Analysis Technical Manual (P/N 702232
Rev2, Affymetrix Inc., Santa Clara, CA, USA). Affymetrix GeneChip1
expression arrays (Human Genome U133 Plus 2.0 Array) were
hybridized for 16 h in a 45 8C incubator, rotated at 60 rpm.
According to the manufacturer’s instructions, the arrays were then
washed and stained using the Fluidics Station 450 and ﬁnally
scanned using the GeneChip1 Scanner 3000 7G. For HL60 and the
primary patient sample, 250 ng of total RNA from each sample
were used to prepare biotinylated fragmented cRNA according to
the GeneChip1 30 IVT Express Kit Manual (PN 702646 Rev1,
Affymetrix Inc., Santa Clara, CA). Affymetrix GeneChip1 expression
arrays (Human Genome U133 Plus 2.0 Array) were hybridized for
16 h in a 45 8C incubator, rotated at 60 rpm. According to the
GeneChip1 Expression Wash, Stain and Scan Manual (PN 702731
Rev2, Affymetrix Inc., Santa Clara, CA) the arrays were then washed
and stained using the Fluidics Station 450 and ﬁnally scanned
using the GeneChip1 Scanner 3000 7G.
2.7. Microarray data analysis
Subsequent analysis of the gene expression data was carried
out in the freely available statistical computing language R
(http://www.r-project.org) using packages available from the
Bioconductor project (www.bioconductor.org). Principal com-
ponent analysis (PCA) was used to visualize the data; using the
‘princomp’ function in Matlab. The raw data was normalized
using the robust multi-array average (RMA) method ﬁrst
suggested by Li and Wong in 2001 [16,17]. In order to search
for the differentially expressed genes between the AKN-028
treated samples and the control group only these samples were
normalized together and an empirical Bayes moderated t-test
was then applied [18], using the ‘limma’ package [19]. To
address the problem with multiple testing, the p-values were
adjusted using the method of Benjamini and Hochberg [20].
To further characterize the actions of AKN-028, we performed
a gene set enrichment analysis (GSEA) as described previously
[8,21]. To establish the rank lists, average fold change was used
as rank metric for AKN-028-treated cells versus control; fold
change for midostaurin-treated samples versus control was used
for comparison.
2.8. Tyrosine kinase and serine/threonine kinase activity proﬁling
using PamChip1 peptide microarrays
Tyrosine kinase activity proﬁles were determined using the
PamChip1 tyrosine kinase peptide microarray system (PamGene
International B.V., ‘s-Hertogenbosch, The Netherlands), as described
previously [22]. Serine/threonine kinase activity proﬁles were
determined with the serine/threonine PamChip1 peptide micro-
array system (PamGene International B.V.). The arrays contain 144
peptides of which two are prephosphorylated on the PamChip1
serine/threonine kinase peptide arrays and one on the PamChip1
tyrosine kinase peptide array (serving as positive controls). The
tyrosine kinase microarray also contains one negative control.
Cryopreserved leukemic cells were thawed and then lysed in M-PER
Mammalian Extraction Buffer containing phosphatase and protease
inhibitors (#78501, #78426, #78415, Thermo Scientiﬁc, Waltham,
MA, USA), incubated on ice for 15 min and centrifuged at 10,000  g
for 15 min at 4 8C after which the supernatant was collected and
stored in aliquots at 80 8C. The protein concentrations in the lysates
were determined according to the manufacturer’s instruction using
the Micro BCATM Protein Assay kit (#23235, Thermo Scientiﬁc).
The incubations were performed on the PamStation112
according to the instructions in the PamGene PTK assay kit
(PamGene International B.V.). In short, before addition of the
samples, the PamChip1 arrays were blocked with 2% bovine serumalbumin (BSA) according to the standard settings for the
PamStation112. The reaction mixture contained 100 mM ATP,
0.5% DMSO and 2–5 mg protein lysate per array for the tyrosine
kinase assay. Since the optimal amount of lysate per array varied
depending on the activity of the protein kinases in the lysate with
regards to signal intensity, the input concentration for the tyrosine
kinase assay was optimized for each sample. AKN-028 or vehicle
(DMSO) was added as a spike in to the incubations in concentra-
tions ranging from 0 to 25 mM. The concentration range of the
compound was chosen in order to obtain complete in vitro efﬁcacy.
Peptide phosphorylation of the 144 peptides on the array was
detected during the kinetic run with the FITC labeled anti-
phosphotyrosine antibody PY20. Images of the arrays were taken
every 5 cycles for 60 cycles. The arrays were then washed and a set
of images was taken at different exposure times. Experiments were
performed in triplicates or more. Serine/threonine kinase activity
was measured for the three patient samples, essentially as
described for the tyrosine kinase assay. Peptide phosphorylation
was detected with a mixture of anti-phosphoserine/threonine
antibodies and visualized with a FITC labeled secondary antibody.
To account for differences in protein input, signal intensities were
normalized to the array mean, 1 mg per array was used for all
samples in the serine/threonine kinase assay after optimization of
the sample input, 10 mM AKN-028, 10 mM UCN-01 or vehicle
(DMSO) was added as a spike in to the incubations.
After visual check of correct peptide spot identiﬁcation, signal
intensities on each peptide at each time point were quantiﬁed
using the Bionavigator software (PamGene International BV). Data
analysis was performed with the same software package. Signal
intensities minus the local background of the after wash images
were normalized to exposure time, excluding signals on peptides
where more than 5% of the pixels were saturated. For the tyrosine
kinase assay, three peptides had to be excluded because saturation
occurred at all exposure times. The kinetics of the tyrosine kinase
reaction was used for quality control: only those peptides were
included where signals increased in time in at least one sample in
the absence of AKN-028. Furthermore, signal intensity had to be
higher than the local background value. For analysis of the serine/
threonine data, only peptides that showed ATP dependent signals
were included in the analysis.
2.9. Statistical analysis
Statistical analysis of the gene expression data is described in
detail in Section 2.7 and the IC50 calculations in Section 2.4. For
comparison between groups in the kinase activity assays, Student’s
t-test was used, p < 0.05 was considered signiﬁcant.
3. Results
3.1. AKN-028 induces cell cycle arrest in the MV4-11 cell line
For the cell cycle distribution analysis, the MV4-11 cells were
induced with AKN-028, the positive control ATRA or vehicle
control only (0.1% DMSO) and cell cycle distribution analyzed after
72 h exposure. Treatment with AKN-028, as well as ATRA resulted
in G0/G1 cell cycle arrest and increased cell death, as observed by
the increased size of the pre-G1 phase nuclei peak (Fig. 1a–c).
Notably, the cell cycle effect of AKN-028 displayed a dose
dependent pattern as shown in Fig. 1d.
3.2. Downregulated genes in AKN-028 treated cells are associated
with the Myc pathway
The cytotoxic activity of AKN-028 in the AML cell lines MV4-11
and HL60 as well as in the three primary AML samples has
Fig. 1. Cell cycle distribution of MV4-11 cells 72 h after induction with vehicle (a), 0.1 mM AKN-028 (b) or 0.5 mM of positive control ATRA (c). N = 4, one typical experiment
analyzed by ﬂow cytometry displayed. (d) shows the percentage of MV4-11 cells in different phases of the cell cycle after treatment with 0.025, 0.05 or 0.1 mM of AKN-028,
0.5 mM of positive control ATRA or vehicle only (0.1% DMSO), mean values, error bars represent SEM.
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of reference compound midostaurin was now evaluated in the cell
lines and in UPN2 by use of the FMCA (IC50 values for MV4-11:
0.0199 mM, HL60: 20.3 mM and UPN2: 0.465 mM). Cell lines were
examined regarding overall quantitative FLT3 expression, display-
ing a ratio FLT3/GUSB  100 of 88.52 for MV4-11 and 8.114 for
HL60.
The effects of AKN-028 in AML were further investigated by
measurement of changes in gene expression in compound-
treated AML cell lines and primary cells from one AML patient
(UPN2). The MV4-11, HL60 and UPN2 cells were exposed to
10 mM AKN-028, the reference compound midostaurin, or
vehicle (DMSO) for 6 h. Treatment with AKN-028 resulted in
signiﬁcantly altered gene expression, with similar pattern for all
samples in all three cell types tested, compared to the vehicle-
treated cells. In total, 430 transcripts were downregulated and
280 were upregulated (>twofold difference, mean signal >5 and
adjusted p < 0.05).
A gene set enrichment analysis (GSEA) of microarray results
generated from AKN-028 or midostaurin treated leukemia cells
and common for all samples was performed to promote better
understanding of the mode of action of the compounds in AML.
The analysis revealed an enrichment of predeﬁned genes
associated with the proto-oncogene c-Myc [23] among the
downregulated genes in both the AKN-028 and the multikinase
inhibitor midostaurin treated cells (Fig. 2).3.3. AKN-028 sensitive AML cells tend to show a higher overall
tyrosine kinase activity than more resistant samples
To further investigate the actions of AKN-028, the tyrosine
kinase activity proﬁle was measured in lysates from the two AML
cell lines as well as the three primary AML samples. The AML cell
lines and the primary patient samples were selected from their
previously known in vitro sensitivity to AKN-028 (IC50 values for
MV4-11: 0.0283 mM, HL60: 5.87 mM, UPN1: 11.3 mM, UPN2:
0.890 mM and UPN3: 0.420 mM [3]). Altogether, the patient sample
UPN1 and the cell line HL60 represent relatively resistant samples,
while UPN2 is an intermediate variant and UPN3 and MV4-11 are
relatively sensitive to AKN-028.
Comparison of the tyrosine kinase activity proﬁle between the
AKN-028 resistant and sensitive cell types revealed a signiﬁcant
difference (p-value <0.05, Student’s t-test) in basal phosphoryla-
tion level in 57 of the 141 peptide substrates tested. Both cell lines
were actively proliferating at a comparable rate when the lysates
were prepared. For primary AML samples, this pattern was even
more pronounced with 73 out of the 141 peptides showing
signiﬁcantly higher peptide phosphorylation signals (p-value
<0.05) in UPN3 as compared to the more resistant UPN1. The
differences in tyrosine kinase activity as read out on the peptides
with the highest signal intensity are presented in Fig. 3, showing
identical peptide sets for the different cell types. We found several
peptides that are phosphorylated by tyrosine kinases involved in
Fig. 2. Gene set enrichment analysis based on microarray data from leukemic cells
(cell lines MV4-11, HL60 and primary AML sample UPN2) treated with 10 mM of
AKN-028 (a) or midostaurin (b) compared to vehicle control. Genes have been rank-
ordered according to their relative fold change. Enrichment proﬁles show a
downregulation of Myc-associated genes upon treatment with AKN-028 or
midostaurin.
Fig. 3. The twelve peptides with the highest basal signal after phosphorylation by
tyrosine kinases present in lysates of three primary AML samples (a) and two AML
cell lines (b), error bars represent SD, n = 3–6. UPN1 and cell line HL60 represent
more resistant samples, UPN2 an intermediate variant and UPN3 and cell line MV4-
11 more sensitive ones with regards to cytotoxic activity of AKN-028 in vitro.
Results are presented as signal intensity/mg protein.
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related kinases.
3.4. Tyrosine kinase activity in AML cells is inhibited by AKN-028 in a
dose dependent manner
The tyrosine kinase activity in lysates from AML cell lines and
from the three primary patients was analyzed in the presence of
AKN-028. In all samples tested, 10 mM of AKN-028 reduced
peptide tyrosine phosphorylation to approximately the same level
(Fig. 4a and b). Since all samples reached the same level of
inhibition, and bearing in mind the difference between sensitiveand resistant samples regarding basal tyrosine kinase activity, the
results indicate that the variation in sensitivity to AKN-028 in vitro
might be related to the difference in overall tyrosine kinase activity
between different AML cells. Using four different concentrations of
AKN-028 (0–25 mM), there was a dose-dependent inhibition
(Fig. 4c) in all cell samples. As with the peptides with the highest
overall tyrosine phosphorylation signal, we identiﬁed several
peptides phosphorylated by kinases involved in the pathogenesis
of malignancies among peptides whose phosphorylation was most
inhibited by AKN-028.
Serine/threonine kinase activity of the three patient samples
showed at most 30% difference in signal intensity between the
samples, whereas more than ﬁve-fold differences were observed
for the tyrosine kinase activity (see Figs. 4 and 5). Since such small
differences could also be due to differences in input concentration,
signal intensities were normalized to the mean signal per array, to
eliminate such input differences (Fig. 5a). In this analysis, only 27,
16, and 15 peptides of the 142 tested were found to be signiﬁcantly
different between UPN2 and UPN3, UPN1 and UPN3 and UPN1 and
UPN2 respectively. While 10 mM AKN-028 led to more than 50%
inhibition of tyrosine kinase activity, serine/threonine kinase
activity was hardly affected (Fig. 5b). At most, 20–30% inhibition
was seen in one sample (UPN2), which indicates that AKN-028
does not have strong overall inhibitory action on serine/threonine
kinases.
4. Discussion
We have shown that the tyrosine kinase inhibitor (TKI) AKN-
028 induces a dose-dependent accumulation of cells in the G0/1
Fig. 4. Tyrosine kinase activity proﬁles from three AML primary patient samples (a) and HL60 and MV4-11 cell lines (b) with 10 mM of AKN-028 or vehicle (DMSO) only
present during the assay. The peptide selection was made as described in Section 2. (c) shows the effect of the presence of increasing concentrations of AKN-028 in the assay
on tyrosine kinase activity in AML patient samples. Signal intensity expressed as a ratio between lysate without and with the kinase inhibitor AKN-028, results presented as %
inhibition.
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TKIs [4,24] and compatible with a downregulation of both cyclin D-
dependent kinases (Cdks) and Myc. The cell cycle arrest also offers
a possible explanation for the sequence-dependent in vitro
synergy previously reported when AKN-028 is combined with
cytarabine or daunorubicin, i.e. the standard cytotoxic agents used
in AML therapy [3].
Using a gene set enrichment analysis of microarray results
generated from AKN-028 or midostaurin treated leukemia cells,
we observed an enrichment of the Myc-pathway among the
downregulated genes for both compounds. The proto-oncogene
c-Myc encodes the transcription factor Myc, a signiﬁcant
regulator in hematopoiesis, which plays an important role in
the control of cell proliferation, differentiation and apoptosis.
Myc dysregulation is common in many types of malignant
diseases including AML [23,25]. Indeed, the fusion proteins
AML1-ETO, PML/RARa and PLZF/RARa, all associated with AML,
along with activating mutations in FLT3, have been reported to
cause upregulation of Myc [26,27]. Recently, bromodomain-
containing 4 (Brd4) has been identiﬁed as a therapeutic target in
AML. The suppression of Brd4 leads to cell cycle arrest and
apoptosis, an effect, at least partly, due to the global reduction in
expression of Myc target genes [28]. We know from previous
studies that AKN-028 will induce apoptosis within 12–48 h
and that <25% of MV4-11 cells will be alive after 72 h at the
concentration used in the cell cycle experiments (0.1 mM) [3]. We
thus hypothesize that the reduction in expression of Myc target
genes after AKN-028-treatment, may be the cause of the observedcell cycle G1 arrest and subsequent apoptosis in MV4-11 cells, but
the actual sequence of events remains to be explored.
Searching for differentially expressed genes, our analysis
showed that treatment with AKN-028 resulted in signiﬁcantly
altered gene expression in all three cell samples tested, compared
to vehicle control treated cells. Although the pattern for the
downregulated genes after AKN-028 treatment seemed to have
similarities with the gene expression pattern of midostaurin-
treated cells, the pattern for the upregulated genes appeared to be
unique, affecting genes involved in cellular replication processes.
The impact of this is not fully elucidated, further studies are
ongoing.
We have previously shown that AKN-028 does not solely
exercise its effect through FLT3 inhibition, but also gives a potent
KIT inhibition in a cellular assay. Furthermore, AKN-028 inhibits
CLK kinases and RPS6K when tested in on-target biochemical and
cellular assays [3]. Since direct target–compound interaction not
necessarily gives the full explanation of the complete effect on
signaling pathways of a compound; a global kinase activity
proﬁling technique [22] was used in this study to further
understand the cellular effects of AKN-028 in AML samples. In
this current study, instead of measuring phosphorylation levels of
speciﬁc proteins, we wanted to measure kinase activity directly
and the modulation thereof by AKN-028, using the peptides on the
chip as a readout. As several peptides represent the activity of a
single kinase, the effect of a compound can also be detected by
multiple peptides. In addition, single peptides on the chip can be
recognized by more than one tyrosine kinase due to the
Fig. 5. Difference in basal phosphorylation activities after normalization to the array mean between three AML primary patient samples in the serine/threonine kinase assay
(a) and after the addition of vehicle (DMSO), 10 mM of AKN-028 or the positive control UCN01 (b). Signal intensity in (b) is expressed as a ratio between lysate without and
with compound addition, results presented as % inhibition.
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FLT3 are part of signaling networks with multiple feedback
mechanisms. A kinomic approach enables measurement of overall
kinase activity of a signaling network executed by a relatively
speciﬁc inhibitor as AKN-028 in an AML cell. Large differences in
tyrosine kinase activity were observed between the sensitive and
resistant samples, whereas differences in serine/threonine kinase
activity were small. Among the peptides with the highest overall
tyrosine phosphorylation signal, as well as those whose phos-
phorylation was most inhibited by AKN-028, we identiﬁed several
peptides phosphorylated by kinases involved in the pathogenesis
of malignancies, including Src and Src-related kinases such as FER,
FYN and FYN-related kinase (FRK). These kinases are important
mediators of tumor cell proliferation and survival, and act, at least
partly, through extensive interaction with receptor tyrosine
kinases. Src activation also stabilizes focal adhesion complexes
such as paxillin and focal adhesion kinase (FAK) [29]. Indeed,
recent studies by Leischner et al. identify Src as a signaling
mediator in FLT3-ITD AML, leading to activation of STAT5 [30].
Furthermore kinases FER and FES and PLCG1 are linked to FLT3
activity, as well as activation of MAPK and AKT/mTOR pathways
[31,32].
In addition, the Cdk2 peptide sequence was among the top
peptides whose activity was inhibited by AKN-028. Cdks are a
family of kinases, forming heterodimeric complexes with a cyclin
partner to become active. Cdk 2, 4 and 6 have important roles in
cell cycle management as regulators of the transition between G1/
S, S-phase progression and G2/M transition [33,34]. Moreover,
downregulation of Myc genes has been shown to lead to a
reduction in Cdk2 kinase activity, compatible with our observed
results [34]. Interestingly, Myc signaling is induced by growthfactors, including FLT3, and mediated by cellular Src, thus
providing a possible mechanism for the Myc downregulation
[26,35]. As previously shown, AKN-028 induces an inhibition of
FLT3 within minutes [3] and we now show a reduced phosphor-
ylation of peptides phosphorylated by kinases such as Src and FRK
within hours. Downregulation of Myc-associated genes was
detected after 6 h, thereby preceding both apoptosis [3] and cell
cycle effects in AML cells. In summary, we hypothesize that
although AKN-028 is not a direct inhibitor of Src in a biochemical
assay (data not shown), inhibition of FLT3 might reduce the
activity of Src and Src related kinases, in turn causing reduced
activity in the Myc-pathway, leading to subsequent cell cycle
arrest and/or apoptosis. Evidently, this hypothesis needs to be
further investigated, including studies of speciﬁc inhibition of Src
activity in a cellular assay are warranted.
Results from the tyrosine kinase activity proﬁling suggest that
AML samples sensitive to AKN-028 have a higher overall kinase
activity than the more resistant ones. These ﬁndings imply a
variance in biology between different AML patients, not necessarily
linked to known mutations or karyotypic alterations. Nevertheless –
all samples showed a dose dependent inhibition to AKN-028 and
reached approximately the same level of activity after inhibition.
The results suggest that the difference in cytotoxic activity of AKN-
028 may be due to the variation in basal overall tyrosine kinase
activity between cells. Obviously, larger sets of patient samples
are needed before making wider generalizations, but one may
speculate that tyrosine kinase activity proﬁling could, in the future,
become an additional way of classifying AML cases in order to
predict good responders, i.e. serve as a predictive biomarker.
In summary, we investigated the mode of action of the FLT3 and
KIT inhibitor AKN-028 in AML, showing that it induces a G0/1 cell
A. Eriksson et al. / Biochemical Pharmacology 87 (2014) 284–291 291cycle arrest. Gene expression proﬁling experiments revealed a
downregulation of Myc-associated genes. Global tyrosine kinase
proﬁling showed that AKN-028 affects several kinases/signaling
pathways, including Cdk2, Src and Src-related kinases, which are
important for tumor cell proliferation and survival. AML cells with
high global tyrosine kinase activity were more sensitive to the
cytotoxic effect of AKN-028 in vitro.
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